Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 9/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 3/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.56 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602096 | 0.82 | PTGS2 (0.69) | PTGS1PTGS2MAPTSLC22A6CXCR1 | |
| SCHEMBL129343 | 0.79 | ENPP2 (0.50) | MAPTSMN1; SMN2HPGDKDM4EALDH1A1 | |
| SCHEMBL31430960 | 0.79 | ENPP2 (0.50) | MAPTSMN1; SMN2HPGDKDM4EALDH1A1 | |
| SCHEMBL22023201 | 0.79 | HSD17B10 (0.47) | HPGDKDM4EALDH1A1HSD17B10MGLL | |
| SCHEMBL2722929 | 0.78 | FFAR1 (0.46) | HPGDKDM4EALDH1A1MGLL | |
| SCHEMBL8136361 | 0.78 | PTGS1 (0.59) | PTGS1PTGS2MAPTSLC22A6CXCR1 | |
| SCHEMBL8136359 | 0.78 | PTGS1 (0.59) | PTGS1PTGS2MAPTSLC22A6CXCR1 | |
| SCHEMBL2183822 | 0.78 | PTGS1 (0.59) | PTGS1PTGS2MAPTSLC22A6CXCR1 | |
| SCHEMBL1345333 | 0.77 | PTGS1 (0.62) | PTGS1PTGS2MAPTSLC22A6CXCR1 | |
| SCHEMBL3857739 | 0.77 | PTGS2 (0.57) | PTGS1PTGS2SLC22A6CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912209-B2 | Rock inhibitors | AMAKEM NV (BE) | 2014-12-16 | — | — | US | disclosed |
| US-8815873-B2 | Heterocyclic amides as rock inhibitors | AMAKEM NV (BE) | 2014-08-26 | — | — | US | disclosed |
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2013-09-26 | — | — | US | disclosed |
| EP-2626348-A1 | Heterocyclic amides as rock inhibitors | Amakem NV (BE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2542528-B1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2542528-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | Amakem NV (BE) | 2013-01-09 | — | — | EP | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
| EP-1891019-B1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1891019-A2 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| CN-101039920-A | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | AVENTIS PHARMA INC (US) | 2007-09-19 | — | — | CN | disclosed |
| WO-2006044732-A2 | 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | PTGS1 3474/4885PTGS2 3688/4885MAPT 1227/4885 |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | ROCK1, ROCK2, CIT | PTGS1 86/4885PTGS2 147/4885MAPT 1779/4885 |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | ROCK1, ROCK2, CIT | PTGS1 180/4885PTGS2 307/4885MAPT 1033/4885 |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | PTGS1 17/4885PTGS2 11/4885MAPT 3272/4885 |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | PTGS1 17/4885PTGS2 11/4885MAPT 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.